SLAMF7
SLAMF7 Molecule Information
Name:SLAM family member 7
Target Synonym:Novel Ly9;CS1;CD_antigen=CD319;Membrane protein FOAP-12;CRACC;SLAMF7;Protein 19A;SLAM family member 7;CD2 subset 1;CD2-like receptor-activating cytotoxic cells
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved
SLAMF7 Molecule Synonym Name
SLAMF7,CD319,CS1,CRACC,19A,FOAP-12
SLAMF7 Molecule Background
SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.
SLAMF7 References
SLAMF7 Public Drug Information
| Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
| Elotuzumab |
HuLuc-63; BMS-901608; PDL-063 |
Approved |
Abbvie, Bristol-Myers Squibb |
EMPLICITI |
fda |
Multiple myeloma (MM) |
BRISTOL MYERS SQUIBB |
2015-11-30 |
Multiple myeloma (MM) |
Details
|
SLAMF7 Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| UCART-CS1 |
UCART-CS1; UCART-38 |
Phase Ⅰ |
Cellectis, M.D. Anderson Cancer Center |
Multiple myeloma (MM) |
Details
|
| Azintuxizumab vedotin |
ABBV-838 |
Phase Ⅰ |
Abbvie |
Multiple myeloma (MM) |
Details
|
| CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) |
|
Phase Not Specified |
Wuhan Bio-Raid Biotechnology, Tongji Hospital |
hematological malignancies |
Details
|
A-Z
